Patients with refractory autoimmune diseases were recruited to be treated with TyU19 难治性自身免疫性疾病患者被招募接受TyU19治疗 Para_01 本研究招募了一例 SRP-IMNM 和两例 dcSSc 患者,进行了一项由研究者发起的试验,该试验在我机构使用 TyU19 治疗难治性复发自身免疫性疾病(NCT05859997)。
其他CD19 自身免疫病CAR-T: 自2022年Carl June在Cell上发表题为"CAR T therapy extends its reach to autoimmune diseases"的论文起,CD19 CAR-T细胞拦截B细胞驱动的自身免疫性疾病的概念正在逐渐得到验证。 其中一方面,单纯通过靶向CD20造成异常的B细胞耗竭可能还不够,因为B细胞前体(在SSc等适应症中特异性扩增)和...
Given the frequent co-occurrence of autoimmune diseases with lymphoproliferative disorders, such as B-cell non-Hodgkin lymphomas (B-NHL) and multiple myeloma (MM), we evaluated the clinical effect of commercially available CART targeting CD19 and BCMA (CART19 and CARTBCMA) on AD in pts with ...
目的评估糖皮质激素对CD19嵌合抗原受体T细胞(CAR-T细胞)靶向杀瘤过程中增殖的影响。 方法健康志愿者的外周血单个核细胞(PBMC)作为T细胞来源,经CD3磁珠分选及CD19 CAR慢病毒转染制备CD19 CAR-T细胞;采用流式细胞术(FCM)测定CD19 CAR-T细胞转染率及其在培养体系中所占比例;采用CFDA SE细胞增殖示踪荧光探针试剂标记CD...
For MRD/relapse, CR rate to CARTr was 50% (5/10), but 0/8 for nonresponse to CARTi. Toxicity was generally mild, with the only grade ≥3 cytokine release syndrome (n = 6) or neurotoxicity (n = 1) observed in MRD/relapse treatment. Reinfusion of CTL019/tisagenlecleucel or h...
Accordingly, several anti-CD20 monoclonal antibodies have been developed to effectively deplete B-cell populations and manage B-cell malignancies, as well as some inflammatory and autoimmune diseases. The first anti-CD20 monoclonal antibody was Rituximab, which was approved by the FDA in 1997. More ...
Regardless, limiting such toxicities has the potential to broaden the application of CAR T cells in SLE and other autoimmune diseases. Hu19-CD828Z is an anti-CD19 CAR construct with a CD28 co-stimulatory domain that was engineered in its entirety to release lower levels of cytokines by ...
第四代CD19-CART细胞治疗复发/难治成人急性B淋巴细胞白血病的临床研究 背景:传统标准治疗下,成人B-ALL患者的5年生存率为30%-40%.疾病复发和化疗耐受是影响其预后的关键因素,目前尚未有针对复发/难治成人B-ALL的标准挽救方案.靶向CD19的嵌合抗原受体(CAR)T细胞疗法在复发/难治B细胞急性淋巴细胞白血病(B-ALL)患者...
CD5~-B淋巴细胞布鲁顿酪氨酸激酶磷酸化布鲁顿酪氨酸激酶目的自身免疫性溶血性贫血(Autoimmune Hemolytic Anemia,AIHA)/Evans综合征按病因分为原发性和继发性,继发于... 曲莹莹 - 天津医科大学 被引量: 0发表: 0年 伊布替尼联合CD19嵌合抗原受体T细胞治疗慢性淋巴细胞白血病的研究进展 但仍有大部分患者存在原发耐药...
Since their discovery, Tregs have represented attractive candidates for the treatment of autoimmune diseases due to their immunomodulatory properties16. In the context of hematopoietic stem cell transplantation (HSCT) for autoimmune diseases, including SLE17, the restoration of the Treg compartment ...